Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

AI nuclear energy background, future innovation of disruptive technology

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

Rice bioengineer receives support for brain cancer research

Previous article

‘Avatar: The Way of Water’ trailer promises a wet visual spectacle

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News